Drugs /

sabatolimab

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.

Clinical Trials

View Clinical Trials for sabatolimab

Sabatolimab has been investigated in 9 clinical trials, of which 9 are open and 0 are closed. Of the trials investigating sabatolimab, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).

Complex karyotype, Monosomy 7, and NPM1-MLF1 Fusion are the most frequent biomarker inclusion criteria for sabatolimab clinical trials.

Myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia are the most common diseases being investigated in sabatolimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sabatolimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sabatolimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-tim-3 monoclonal antibody mbg453, mbg 453, anti-tim3 checkpoint inhibitor mbg453, mbg453
Drug Target(s) [2]:
HAVCR2
NCIT ID [1]:
C124850

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.